Idorsia Ltd. (IDRSF)
5.38
0.00 (0.00%)
USD |
OTCM |
Oct 12, 16:00
Idorsia Cash from Investing (Quarterly) : -3.521M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.521M |
| March 31, 2026 | -2.070M |
| December 31, 2025 | 6.039M |
| September 30, 2025 | 2.650M |
| June 30, 2025 | -11.11M |
| March 31, 2025 | 7.625M |
| December 31, 2024 | -5.243M |
| September 30, 2024 | -43.71M |
| June 30, 2024 | -0.2875M |
| March 31, 2024 | 351.44M |
| December 31, 2023 | 58.89M |
| September 30, 2023 | 302.19M |
| June 30, 2023 | -3.376M |
| March 31, 2023 | 341.98M |
| December 31, 2022 | 58.48M |
| September 30, 2022 | 118.76M |
| June 30, 2022 | 301.95M |
| March 31, 2022 | 304.43M |
| December 31, 2021 | 193.14M |
| Date | Value |
|---|---|
| September 30, 2021 | -567.21M |
| June 30, 2021 | 170.21M |
| March 31, 2021 | 148.52M |
| December 31, 2020 | -447.53M |
| September 30, 2020 | -158.56M |
| June 30, 2020 | 5.721M |
| March 31, 2020 | -64.32M |
| December 31, 2019 | 4.375M |
| September 30, 2019 | 43.19M |
| June 30, 2019 | -149.55M |
| March 31, 2019 | 28.32M |
| December 31, 2018 | 253.60M |
| September 30, 2018 | -353.83M |
| June 30, 2018 | 131.47M |
| March 31, 2018 | -2.917M |
| December 31, 2017 | -75.86M |
| September 30, 2017 | -0.8932M |
| June 30, 2017 | -402.73M |
| March 31, 2017 | -3.893M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | -49.41M |
| AC Immune SA | -- |
| CRISPR Therapeutics AG | -55.66M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -43.01M |
| Cash from Financing (Quarterly) | 38.69M |
| Free Cash Flow | -172.44M |
| Free Cash Flow Per Share (Quarterly) | -0.1818 |
| Free Cash Flow to Equity (Quarterly) | -41.35M |
| Free Cash Flow to Firm (Quarterly) | -18.59M |
| Free Cash Flow Yield | -13.20% |